Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial

J Allergy Clin Immunol. 2017 Sep;140(3):870-873.e5. doi: 10.1016/j.jaci.2017.01.042. Epub 2017 Apr 4.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Allergic Agents / therapeutic use*
  • Double-Blind Method
  • Drug Resistance
  • Female
  • Histamine Antagonists / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Omalizumab / therapeutic use*
  • Treatment Outcome
  • Urticaria / drug therapy*

Substances

  • Anti-Allergic Agents
  • Histamine Antagonists
  • Omalizumab

Associated data

  • EudraCT/2011-005615-87
  • ClinicalTrials.gov/NCT02169115